 Today I have the pleasure of speaking with Dr. Ludwig Agner. How are you today? Great, thanks very much. It is a real pleasure to meet you. You're an age-juvenation specialist and neuroscientist that's recently joined Intel Genetics' Scientific Board. Can you tell us a little bit more about what you do? Well, I'm a neuroscientist working since 20-25 years on regeneration, brain regeneration. More lately, focusing more on rejuvenation. So that goes beyond, let's say, the last, you know, the attempts of the last decades where people just try to protect neurons from dying. Now we are looking at the aged brain because aging is the main risk factor for many of the diseases that we are interested in. For example, dementia, Alzheimer's dementia. And so we would like to go beyond just protecting neurons from dying, but we would really like to make the aged brain younger, with other words, really try to rejuvenate the aged brain with the aim, basically, to finally also develop therapies for dementia, for Alzheimer's and so on. Okay, this is a very exciting industry and I'll tell you, my brain could use some work here. So in particular, you speak a lot about drug repurposing, the drug delivery in drug repurposing. For some of our investors out there that may not be familiar with this, can you tell us a little bit more about what this means? Well drug repurposing is a very, also let's say innovative and very young way to come up with new drugs for certain diseases. New drugs meaning the new use for already known drugs. Now, if you just look at the cost of drugs to be developed, any kind of completely new drug would cost, I mean these days something like 2.6 billion dollars for each individual drug. So these are huge costs. Now, if you are able to use a drug that has been already developed and used for a certain disease, and you find that this drug might be also useful for another disease, you just take this drug and develop it for this new disease, for this new indication that you are interested in. And that's kind of what repurposing is or repositioning is also called. So looking at Intel GenX's website, the company is very focused on Montelucast, which is used for the treatment of asthma. Can you tell us a little bit more about this? Well Montelucast has been, is already approved and it's on the market since more than 15 years for its use in asthma. That's what it has been developed for. Now, we found out sort of through our basic scientific work that things that happen basically in asthmatic patients in the lung are also present, so the molecular signalings that are present there, they are also, we find them also in the brain of aged people, of aged, along aging, and the signaling mechanisms are already there in brains of neurodegenerative diseases. So basically we sort of found that what is happening in the lung with asthmatic patients is also happening in the aged brain. So that's why we sort of came up with the idea of if we are able to block this, and Montelucast actually does that, that's what it has been developed for in the field of asthma. So if we block these same signalings and signaling molecules and mechanisms in the brain, we might actually be able to rejuvenate the brain or to make the brain younger and to block these signaling mechanisms. So if I understand you correctly, Intel GenX is working with Montelucast. They're looking at the drug repurposing options that you have, and it looks like it might be used for age rejuvenation of the brain. Is that correct? Yes, that's correct, absolutely right. So reviewing Intel GenX's website, obviously drug delivery may have an impact in the drug repurposing. Is that correct and can you explain that a little bit better? Yes, absolutely. I mean, many drugs have been, for example, developed for a certain disease, and even though this drug might work in another disease, you still, especially when we are talking about brain diseases, you still need to improve, for example, this drug in terms of its pharmacokinetic. Can we make this drug better, for example, available to the brain? Can we make it better so that the pharmacokinetic, sort of the speed and the amount of drug that really enters the body, can we improve that? And that's basically sort of what we are trying with Intel GenX because they are specialists in especially that field. So that's why we teamed up with Intel GenX. Well, thank you so much, Dr. Agner, for joining us today. And we look forward to follow-ups with you to see how this is going. Thank you very much.